Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity
worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV) …

Background A life-course immunization approach would enhance the quality of life across
all age groups and improve societal well-being. The herpes zoster (HZ) vaccine is highly …

Given our global interconnectedness, the COVID-19 pandemic highlights the urgency of
building a global system that can support both routine and pandemic/epidemic adult …

The objective of this study was to critically review the cost-effectiveness (CE) of the
recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was …

Objective Although the herpes zoster vaccine has been available in mainland China since
June 2020, residents' knowledge of herpes zoster and the herpes zoster vaccine is poor …

Objectives Comprehensive cost-effectiveness analyses of introducing varicella and/or
herpes zoster vaccination in the Swedish national vaccination programme. Design Cost …

Abstract Background In Australia, a herpes zoster (HZ) vaccination program targeting adults
aged 70 years old with catch-up for those 71-79 years began in November 2016 but there is …

Aim: To assess the epidemiology of HZ disease, its clinical manifestations, coexisting and
post-existing conditions, complications, and management among patients in a primary care …

Objectives To perform a systematic review and meta-analysis to pool the incremental net
benefit (INB) of each herpes zoster vaccine ie Zoster Vaccine Live (ZVL) and Recombinant …

Current vaccination policy in most high-income countries aims to counteract the decline in
cell-mediated immunity to varicella zoster virus that occurs with advancing age or …